AI Terminal
Active Biotech
Declaration of Voting Results & Voting Rights Announcements • Mar 31, 2021
3133_rns_2021-03-31_7efba527-791a-43e7-be29-b20e8594fbc7.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
NUMBER OF SHARES AND VOTES IN ACTIVE BIOTECH
PRESS RELEASE, Lund Sweden, March 31, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI)
The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company's incentive program for the company's employees (Plan 2020/2024).
Today, the last trading day of the month, there are in total 217,971,720 shares and votes in Active Biotech.
For further information, please contact: Hans Kolam, CFO Tel: +46 46 19 20 44 E-mail: [email protected]
Active Biotech is required to publish the information contained in this press release in accordance with the Financial Instruments Trading Act. This information was provided to the media for publication at 08.30 am CET on March 31, 2021.
Active Biotech
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anticancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is advancing to phase II for treatment of noninfectious uveitis during second half of 2021. Please visit www.activebiotech.com for more information.